Canadian CANNAINVESTOR Magazine Canada March / April 2019 | Page 196

MPX: CNX | MPXEF: OTSQB | 52-Week range: $0.22 -$0.99 | Market Cap: $259M
RECENT NEWS
March 5, 2018
MPX Signs Definitive
Agreement to
Expand Its Footprint
in Arizona
About Us
MPX Bioceutical Corporation is a multinational
diversified cannabis company focused on the
medical and adult use cannabis markets.
The company has a growing presence in the
U.S. with imminent plans for ten dispensaries
and four production facilities in four states.
It also has a production facility under
construction in Canada as well as a pending
licence application to Health Canada.
In addition to its well established Melting
Point Extracts (MPX) brand, the company’s
foundation is built on its profitable operations
in Arizona, where it has two fully operational
Health for Life dispensaries and a third slated
to open in Q2/2018. MPX also recently
acquired The Holistic Center, giving it a total of
four dispensaries in this state.
In Nevada, MPX is operating GreenMart,
a fully licensed cultivation, production and
wholesale cannabis business.
Multi-state
We’re replicating
profitable operations and
well-established brands
to build a multi-state
presence
In Massachusetts, the construction of the
first of three dispensaries is underway as is
construction of a cultivation and processing
facility in Falls Rivers.
MPX is also managing three dispensaries and
one production facility in Maryland (which are
not yet operational) and has options to acquire
each facility.
Feb 12, 2018
MPX Announces
Inclusion in Horizons
Emerging Marijuana
Growers Index ETF
On August 23, 2017, the Company was
advised that its application for Licensed
Producer status from Health Canada was
at the Detailed Review and Initiation of
Security Clearance Process stage and has
started construction of its 72,342 square foot
production facility.
With all production facilities, MPX anticipates
that it will have 9 million grams per annum in
cultivation capacity and be able to produce 1.2
million grams of concentrates.
With all production facilities, MPX anticipates
that it will have 9 million grams per annum in
cultivation capacity and be able to produce 1.2
million grams of concentrates.
Multi-national
Most MPX Bioceutical
Corporation’s operations
are U.S.-based, but we
have also applied for a
license in Canada
Estalished brands
Established brands like
MPX, Health4Life, and
Salus BioPharma meet
the needs of adult
recreational and medical
cannabis users
Pharma-grade
We signed a definitive
agreement with Panaxia
to develop proprietary,
smokeless pharma-grade
products using cannabis
2018 MPX Bioceutical Corporation